A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...
Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...
Faricimab helped improve vision in previously untreated patients with neovascular age-related macular degeneration, according to a real-world study presented at Retina 2025. Ferhina S. Ali, MD, MPH, ...
Explore the intricate details of the Age-related Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Age-related Macular ...
Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...
On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.
EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...
Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback